Literature DB >> 15040586

The dark side of C5a in sepsis.

Peter A Ward1.   

Abstract

Sepsis is a major clinical problem for which therapeutic interventions have been largely unsuccessful, in spite of promising strategies that were successful in animals, especially rodents. There is new evidence that sepsis causes excessive activation of the complement system and that this induces paralysis of innate immune functions in phagocytic cells due to effects of the powerful complement-activation product, C5a. This review describes our present understanding of how and why sepsis is a life-threatening condition and how it might be more effectively treated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15040586     DOI: 10.1038/nri1269

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  156 in total

Review 1.  Immune therapy in sepsis: Are we ready to try again?

Authors:  Roger Davies; Kieran O'Dea; Anthony Gordon
Journal:  J Intensive Care Soc       Date:  2018-04-04

2.  Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis.

Authors:  Zoltán H Németh; Balázs Csóka; Jeanette Wilmanski; Dazhong Xu; Qi Lu; Catherine Ledent; Edwin A Deitch; Pál Pacher; Zoltán Spolarics; György Haskó
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

Review 3.  Complement-induced impairment of the innate immune system during sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

4.  The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation.

Authors:  M Harboe; G Ulvund; L Vien; M Fung; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

Review 5.  Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins.

Authors:  Matthew Spite; Charles N Serhan
Journal:  Circ Res       Date:  2010-11-12       Impact factor: 17.367

6.  Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood.

Authors:  Ole-Lars Brekke; Bernt Christian Hellerud; Dorte Christiansen; Hilde Fure; Albert Castellheim; Erik Waage Nielsen; Anne Pharo; Julie Katrine Lindstad; Grethe Bergseth; Graham Leslie; John D Lambris; Petter Brandtzaeg; Tom Eirik Mollnes
Journal:  Mol Immunol       Date:  2011-08-11       Impact factor: 4.407

Review 7.  Complement: a key system for immune surveillance and homeostasis.

Authors:  Daniel Ricklin; George Hajishengallis; Kun Yang; John D Lambris
Journal:  Nat Immunol       Date:  2010-08-19       Impact factor: 25.606

8.  Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis.

Authors:  Ravi Shankar Keshari; Robert Silasi; Narcis Ioan Popescu; Maulin Mukeshchandra Patel; Hala Chaaban; Cristina Lupu; K Mark Coggeshall; Tom Eirik Mollnes; Steven J DeMarco; Florea Lupu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-18       Impact factor: 11.205

9.  RNA interference as a potential therapeutic treatment for inflammation associated lung injury.

Authors:  Joanne Lomas-Neira; Chun-Shiang Chung; Alfred Ayala
Journal:  Int J Clin Exp Med       Date:  2008-02-25

10.  Complement-induced Impairment of the Innate Immune System During Sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.